Can Ozempic and Wegovy Curb Addiction and Other Negative Behaviors?

Scroll through social media for five minutes and you’ll see it: people on
Ozempic or Wegovy saying things like, “I just stopped wanting wine,” “My
late-night snacking vanished,” or even “I don’t feel like gambling
anymore.” It almost sounds like science fiction a weekly shot that not
only helps with weight and blood sugar, but also quiets cravings for
alcohol, cigarettes, or other compulsive behaviors.

So, can Ozempic and Wegovy really curb addiction and other negative
behaviors? The short answer: maybe in some ways, for some people,
but the science is still very young and these medications are not
approved addiction treatments. Let’s unpack what we actually know
so far, what’s still speculation, and why it’s crucial not to treat these
drugs as magic “willpower shots.”

First Things First: What Are Ozempic and Wegovy?

Ozempic and Wegovy are brand-name versions of
semaglutide, a medication in a class called
GLP-1 receptor agonists. Ozempic is approved in the
United States to treat type 2 diabetes and to reduce the risk of
cardiovascular problems in certain people. Wegovy is approved for chronic
weight management in adults and some adolescents with obesity or
overweight and weight-related health conditions.

GLP-1 stands for glucagon-like peptide-1, a hormone your body
naturally produces in the gut. When you eat, GLP-1 helps:

• Trigger insulin release and lower blood sugar
• Slow down stomach emptying so you feel fuller longer
• Send “I’m satisfied” signals to the brain

Semaglutide is like a long-acting, turbo-charged version of your own GLP-1.
It lingers in the body for days and activates GLP-1 receptors in multiple
places including the brain. That brain activity is
where scientists think the link to addiction and compulsion might come in.

Why Is Everyone Suddenly Talking About Addiction and GLP-1 Drugs?

Long before large clinical trials were completed, people taking Ozempic and
Wegovy started posting about unexpected changes: less desire to drink
alcohol, no interest in junk food, or even a sudden “meh” feeling about
shopping, gambling, or scrolling. Media outlets quickly picked up on these
stories, and headlines began to ask whether GLP-1 drugs might be useful for
treating addiction.

Anecdotes are interesting, but they’re not proof. However, they did echo
what basic science had been hinting at for years: GLP-1 doesn’t just act
in the gut; it also affects the brain’s reward circuitry.

How GLP-1 Drugs Affect the Brain’s Reward System

The Reward Circuit in One Minute

Many addictive behaviors from heavy drinking to compulsive gambling tap
into the brain’s reward system. Key players include:

• The ventral tegmental area (VTA), which sends dopamine
  (the “do that again” neurotransmitter) to other brain regions
• The nucleus accumbens, a central hub for motivation and
  reward
• Parts of the prefrontal cortex, which are involved in
  planning, self-control, and decision-making

Substances like alcohol, nicotine, and opioids and behaviors like
gambling or binge eating can repeatedly hit this system, training the
brain to put those rewards at the top of the priority list, sometimes at
the expense of health, relationships, and responsibilities.

GLP-1 Receptors in Reward Pathways

It turns out that GLP-1 receptors are not just in the pancreas and
gut they’re scattered throughout the brain, including the VTA and
nucleus accumbens. Animal and human studies suggest that
activating these receptors can:

• Reduce the “reward value” of food and possibly drugs
• Blunt cue-triggered craving (like seeing a drink or a casino ad)
• Modulate dopamine and other neurotransmitters involved in motivation

Systematic reviews have found that GLP-1 signaling can dampen reward
salience and reduce drug-seeking behavior in preclinical models, and may
influence cravings for both natural rewards (like food) and drugs of abuse.

In plain English: GLP-1 drugs may make rewarding things feel less
overpowering and easier to walk away from. That doesn’t mean cravings
disappear, but the “pull” may weaken for some people.

What Does the Research Actually Show So Far?

Alcohol Use Disorder: Early but Encouraging Data

One of the most talked-about studies was a randomized clinical trial of
low-dose semaglutide in adults with alcohol use disorder. Over nine weeks,
people who received semaglutide:

• Drank less alcohol during a laboratory self-administration test compared
  with those who got a placebo
• Reported fewer heavy-drinking days and lower weekly alcohol craving
  scores
• In a subgroup of smokers, showed a greater reduction in cigarettes per
  day than the placebo group

These effects weren’t universal not every measure improved, and not every
participant responded. But they were strong enough to suggest that
semaglutide may help reduce alcohol intake and craving in at least some
people with alcohol use disorder.

Other early-stage studies and case series are exploring GLP-1 drugs for
alcohol use disorder, and several larger trials are now underway. The
interest is big enough that major research institutions and funding bodies
are closely watching GLP-1 medications as a potential new class of
addiction treatments.

Smoking, Opioids, and Other Substances: Still Very Preliminary

Beyond alcohol, researchers are looking at whether GLP-1 drugs might help
people cut down on:

• Nicotine (cigarettes or vaping)
• Opioids
• Stimulants like cocaine or methamphetamine

Reviews of GLP-1 and substance use suggest that, in animals, these drugs
can reduce self-administration of nicotine, opioids, and stimulants and
blunt relapse-like behavior after abstinence. But human data are still very
limited mostly small pilot studies or observations from diabetes and
obesity trials.

Bottom line: GLP-1 drugs are promising for addiction
research, but we’re not yet at the point where your doctor can say,
“Here’s Wegovy as a standard, proven treatment for nicotine or opioid
addiction.”

Behavioral Addictions: Food, Gambling, Shopping, and Screens

GLP-1 drugs already have well-documented effects on food intake and body
weight, especially for ultra-processed, high-reward foods. That’s part of
how they help people lose weight.

For behavioral addictions like gambling, compulsive shopping, or endless
doom-scrolling, the science is much thinner. We mostly have:

• Anecdotal reports from patients and social media
• Basic science showing GLP-1’s general effect on reward circuits
• Speculative articles from experts connecting the dots

Some people do notice that once they’re on Ozempic or Wegovy, their urge to
gamble, shop, or snack late at night goes way down. Others feel no change
at all, or simply shift from one reward (say, food) to another (like
online shopping). Without robust clinical trials, we can’t say which
experiences are directly due to the drug, which are related to weight loss,
better blood sugar control, improved mood, or simply feeling more in
control overall.

Important Limitations: Why This Is Not a Magic “Anti-Addiction Shot”

As exciting as the early data are, there are several big reasons to be
cautious:

1. Ozempic and Wegovy Are Not Approved for Addiction

In the U.S., Ozempic is approved for type 2 diabetes and certain heart risk
reduction; Wegovy is approved for chronic weight management and some people
with cardiovascular disease and obesity. Neither medication is
approved by the FDA for treating alcohol, nicotine, opioid, or other
substance use disorders. Any use for addiction right now is
strictly off-label and should only be considered under
close medical supervision.

2. The Research Is Early, Small, and Evolving

A handful of promising trials plus animal studies do not equal a full set
of clinical guidelines. We still need:

• Larger, longer studies
• Head-to-head comparisons with existing addiction treatments
• Data on who responds best (and who doesn’t respond at all)
• Clear understanding of the ideal dose for addiction, which may differ from diabetes or weight loss doses

Until then, GLP-1 drugs should be seen as a potential future tool
in addiction medicine, not a replacement for evidence-based treatments we
already have (like counseling, cognitive behavioral therapy, support
groups, and FDA-approved addiction medications).

3. Addiction Is More Than Craving

Even if GLP-1 medications help reduce craving, addiction is complex. It
often involves:

• Underlying mental health conditions (anxiety, depression, trauma)
• Social and environmental factors (stress, relationships, access to care)
• Habits and learned behaviors built over years

Any medication that targets craving alone won’t automatically fix the
emotional, social, and behavioral pieces of addiction. That’s why experts
emphasize combining medication with therapy, social support, and lifestyle
changes not relying on a weekly injection to “solve” addiction in
isolation.

Risks, Side Effects, and Safety Concerns

While social media often focuses on weight loss and reduced cravings, it’s
essential to remember that Ozempic and Wegovy are serious prescription
medications with real risks.

Common Side Effects

Typical side effects include:

• Nausea, vomiting, or diarrhea
• Constipation or stomach pain
• Loss of appetite

These often improve over time as the dose is slowly increased, but not
always.

Serious Risks

The U.S. prescribing information for semaglutide products includes a
boxed warning about thyroid C-cell tumors seen in rodents,
and the drugs are not recommended for people with a personal or family
history of medullary thyroid carcinoma or multiple endocrine neoplasia
syndrome type 2. They can also be associated with:

• Pancreatitis
• Gallbladder problems (like gallstones)
• Severe gastrointestinal side effects
• Risk of low blood sugar when combined with certain diabetes drugs

These medications also aren’t appropriate for everyone, including some
pregnant people, those planning pregnancy, or certain individuals with
existing medical conditions.

Counterfeit and Unapproved Products: A Real Hazard

Because Ozempic and Wegovy are so popular, the FDA has warned about
unapproved, compounded, and counterfeit versions being
sold online and even infiltrating parts of the drug supply chain. These
products may not contain the right active ingredient, may have dangerous
contaminants, or may be dosed incorrectly.

If you and your clinician decide a GLP-1 drug is appropriate, make sure you
obtain it from a licensed pharmacy with a valid prescription not from
random websites, social media sellers, or overseas “research” suppliers.

Nothing in this article is medical advice for your personal
situation. Always talk with your own healthcare professional
before starting, stopping, or changing medications, especially if you’re
dealing with addiction, mental health concerns, or chronic health
conditions.

Who Might Eventually Benefit Most If the Research Holds Up?

If ongoing studies confirm benefits for addiction, GLP-1 medications might
be especially useful for people who:

• Have type 2 diabetes or obesity and also struggle with
  alcohol or nicotine use
• Have already tried traditional addiction treatments but still experience
  intense cravings
• Are at high medical risk from both their metabolic disease and their
  substance use

In that scenario, semaglutide could potentially tackle multiple problems at
once: weight, blood sugar, cardiovascular risk, and possibly craving. But
again, that’s a future vision not today’s standard of care.

Questions to Ask Your Healthcare Team

If you’re curious about GLP-1 drugs and how they might interact with
addiction or negative behaviors, consider asking your healthcare
professional:

• Is Ozempic or Wegovy medically appropriate for me based on my weight,
  diabetes status, and overall health?
• Do I take any medications or have conditions that would make GLP-1 drugs
  unsafe?
• If I’m dealing with alcohol, nicotine, or other substance use issues,
  what evidence-based treatments should I consider right now?
• If I start a GLP-1 medication, how will we monitor its effects on my
  cravings, mood, and side effects over time?
• How can we combine medication with counseling, support groups, or other
  therapies to give me the best chance at long-term change?

The Bottom Line: Can Ozempic and Wegovy Curb Addiction and Negative Behaviors?

Here’s the big picture:

• Yes, semaglutide (Ozempic, Wegovy) clearly affects the brain’s
  reward system and can dampen cravings for food and, in some
  early studies, alcohol and possibly nicotine.
• Early research on addiction is promising but not definitive.
  We have hopeful signals, particularly for alcohol use disorder, but we
  don’t yet have enough data to treat these drugs as established addiction
  medications.
• These medications are not FDA-approved for addiction treatment.
  Use for that purpose is off-label and should only happen under careful
  medical supervision, ideally as part of a broader treatment plan.
• They carry real risks and side effects, and counterfeit
  or unapproved versions are a serious safety issue.
• Addiction is bigger than craving alone. Even if
  semaglutide helps with urges, therapy, social support, and lifestyle
  changes remain crucial.

So, can Ozempic and Wegovy curb addiction and other negative behaviors?
Possibly, in a limited and still-being-studied way especially for
alcohol but they’re not a silver bullet. Think of them less as a
magic eraser and more as a potential future tool in a larger toolkit for
both metabolic health and addiction, with a lot more science still to come.

Real-World Experiences: What People Notice (and Why We Still Need Caution)

While researchers race to produce more data, people taking Ozempic and
Wegovy continue to share their day-to-day experiences. These stories do
not replace clinical trials, but they can help us understand how
GLP-1 drugs feel in real life and where expectations can easily drift
into hype.

Consider a composite example we’ll call Alex, based on
typical patient reports. Alex started Wegovy to address obesity and
prediabetes. Before treatment, Friday nights meant a bottle of wine, a few
cigarettes with friends, and late-night delivery food. A month into weekly
injections, Alex noticed something unexpected: the wine no longer tasted
as appealing, the urge to smoke faded, and halfway through a burger, the
feeling was, “I’m good, actually.”

For Alex, the shift felt dramatic almost like someone had turned the
volume down on multiple cravings at once. Workweek productivity improved,
sleep got better, and hangovers mostly disappeared. It would be easy to
look at that experience and say, “Problem solved. Wegovy cured my bad
habits.”

But zoom in further and the picture gets more nuanced. Alex was also:

• Meeting regularly with a therapist to address stress and emotional
  eating
• Using a support app to track alcohol intake and set goals around
  drinking
• Getting consistent positive reinforcement from seeing the number on the
  scale go down and bloodwork improve

All of that matters. The medication may have lowered craving and made it
easier to say “no,” but counseling, structure, and health wins likely
reinforced those changes. In other words, Wegovy may have opened a window;
Alex still had to walk through it.

Another composite example: Jordan started Ozempic for type
2 diabetes. Jordan had a long history of heavy drinking and hoped the drug
would quiet alcohol cravings. But after several months on treatment,
Jordan’s blood sugar and weight improved while drinking patterns stayed
mostly the same. The takeaway here is just as important: not
everyone feels a big change in their addictive behaviors, even if
they benefit metabolically.

Stories like Alex’s and Jordan’s highlight three key points:

• People respond differently. Some feel a big decrease in
  cravings; others don’t. We don’t yet know which biological or
  psychological factors predict who benefits.
• Context matters. Therapy, social support, and lifestyle
  shifts can amplify (or sometimes overshadow) the effects of the
  medication.
• Expectations can shape perception. When you’ve heard
  over and over that Ozempic “kills cravings,” it’s easy to interpret any
  small change as proof of a massive effect or to feel discouraged if
  your experience doesn’t match the hype.

For people living with addiction, this can be emotionally loaded. Some may
feel hopeful that GLP-1 medications could finally give them an edge
against cravings. Others may feel frustrated or even guilty if the drug
doesn’t work for them the way it seems to for others online. That’s why
it’s so important to talk openly with your care team about goals,
expectations, and mental health support while using any GLP-1 medication.

Ultimately, real-world experiences suggest that Ozempic and Wegovy can, for
some people, make negative behaviors easier to walk away from especially
when those behaviors are tightly tied to eating and drinking. But the
stories also underline the same message researchers keep repeating:
these drugs are powerful tools, not magic spells. They may
help tip the balance in your favor, but lasting change usually comes from
combining medication with support, skills, and self-understanding.